ViroPharma SG&A Expense Quarterly:
42.72M for March 31, 2013ViroPharma Historical SG&A Expense Quarterly Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | 42.72M |
| Dec. 31, 2012 | 50.98M |
| Sept. 30, 2012 | 44.29M |
| June 30, 2012 | 40.88M |
| March 31, 2012 | 37.95M |
| Dec. 31, 2011 | 36.05M |
| Sept. 30, 2011 | 31.35M |
| June 30, 2011 | 32.09M |
| March 31, 2011 | 28.31M |
| Dec. 31, 2010 | 24.33M |
| Sept. 30, 2010 | 24.99M |
| June 30, 2010 | 25.42M |
| March 31, 2010 | 20.92M |
| Dec. 31, 2009 | 21.18M |
| Sept. 30, 2009 | 20.15M |
| June 30, 2009 | 23.61M |
| March 31, 2009 | 24.26M |
| Dec. 31, 2008 | 24.20M |
| Sept. 30, 2008 | 14.08M |
| June 30, 2008 | 16.14M |
| March 31, 2008 | Go Pro |
| Dec. 31, 2007 | Go Pro |
| Sept. 30, 2007 | Go Pro |
| June 30, 2007 | Go Pro |
| March 31, 2007 | Go Pro |
| Dec. 31, 2006 | Go Pro |
| Sept. 30, 2006 | Go Pro |
| June 30, 2006 | Go Pro |
| March 31, 2006 | Go Pro |
| Dec. 31, 2005 | Go Pro |
| Sept. 30, 2005 | Go Pro |
| June 30, 2005 | Go Pro |
| March 31, 2005 | Go Pro |
| Dec. 31, 2004 | Go Pro |
| Sept. 30, 2004 | Go Pro |
| June 30, 2004 | Go Pro |
| March 31, 2004 | Go Pro |
| Dec. 31, 2003 | Go Pro |
| Sept. 30, 2003 | Go Pro |
| June 30, 2003 | Go Pro |
| March 31, 2003 | Go Pro |
| Dec. 31, 2002 | Go Pro |
| Sept. 30, 2002 | Go Pro |
| June 30, 2002 | Go Pro |
| March 31, 2002 | Go Pro |
| Dec. 31, 2001 | Go Pro |
| Sept. 30, 2001 | Go Pro |
| June 30, 2001 | Go Pro |
| March 31, 2001 | Go Pro |
| Dec. 31, 2000 | Go Pro |
About SG&A Expense
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
The details of how SG&A expenses are calculated vary widely from company to company, so YCharts recommends looking at the annual report (10-k) an investor is interested in dissecting this number further.
Learn More
VPHM SG&A Expense Quarterly Benchmarks
| Companies | |
|---|---|
| Optimer Pharmaceuticals | 34.95M |
| Halozyme Therapeutics | 6.979M |
| Incyte | 22.26M |
VPHM SG&A Expense Quarterly Rankings
| Overall |
78th percentile 1664 of 7590 |
| Sector |
77th percentile 144 of 651 in Healthcare |
| Industry |
91st percentile 20 of 238 in Biotechnology |
VPHM SG&A Expense Quarterly Range, Past 5 Years
| Minimum | 14.08M | Sep 2008 |
| Maximum | 50.98M | Dec 2012 |
| Average | 29.20M |
